The company is still sitting on a gigantic war chest – a cash position of almost EUR18 billion – inherited from its Covid vaccine windfall.
As the latter is depleting at a rapid pace, BioNTech’s research efforts are now focused on a wide range of oncology programs.
Adjusted for cash, current marke…
© MarketScreener.com 2024
As the latter is depleting at a rapid pace, BioNTech’s research efforts are now focused on a wide range of oncology programs.
Adjusted for cash, current marke…
© MarketScreener.com 2024